EVALUATION OF THE EFFECT OF FAVIPIRAVIR ON MANAGEMENT PATIENT WITH COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201028049175N1

Enrollment

114

Registered

2020-12-12

Start date

2020-11-21

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus disease 2019 (COVID19). COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Favipiravir tablet of FUJIFILM company will be given to the patients. The dose is 1600 mg twice daily on first day and days 2–7: 600 mg twice daily. Intervention 2:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All of patients with COVID19 referred to Valiasr and Khansari hospital All of patients in subgroup 3 of hospitalization

Exclusion criteria

Exclusion criteria: Patients that present allergic reaction to the drug Patients with deterioration of symptomps after drug usage Renal failure manifestation in patients Heart failure manifestation in patients Pregnancy

Design outcomes

Primary

Measure	Time frame
Severity of coronavirus 2019. Timepoint: Before prescription of drug and then every day until 7 days. Method of measurement: pulse oximetry, resspiratory rate, heart rate, CT scan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehnam Mahmoudieh

Arak University of Medical Sciences

behnammahmoodiyeh@gmail.com086-32222003-8

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026